Orexi T cells reprogram the TMEs in immune-competent hosts. (A) C57/BL6 mice underwent engraftment subcutaneously with 2e6 B16F10 tumor cells and, after 4 days, were treated with PBS, mock-transduced, or CV1-transduced PMEL T cells. (B) Tumors were harvested and analyzed for MHCII expression, shown for representative histograms, and quantified in (C) and (D). (E) CD45⁺ cells from harvested B16 tumors were gated for CD11b vs CD11c expression, representative contour plot shown with quantifications in (F). Statistics were performed using student t test. FMO, fluorescence minus one; PBS, phosphate-buffered saline.